RATIO-RISPERIDONE TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

RISPERIDONE

Предлага се от:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

АТС код:

N05AX08

INN (Международно Name):

RISPERIDONE

дозиране:

3.0MG

Лекарствена форма:

TABLET

Композиция:

RISPERIDONE 3.0MG

Начин на приложение:

ORAL

Броя в опаковка:

60/250

Вид предписание :

Prescription

Терапевтична област:

ATYPICAL ANTIPSYCHOTICS

Каталог на резюме:

Active ingredient group (AIG) number: 0124332002; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2015-10-26

Данни за продукта

_ _
RATIO-RISPERIDONE_ - Product Monograph _
_Page 1 of 56_
PRODUCT MONOGRAPH
RATIO-RISPERIDONE
RISPERIDONE TABLETS
0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG AND 4 MG
ANTIPSYCHOTIC AGENT
RATIOPHARM INC.
17 800, Lapointe
Mirabel, Quebec
Canada, J7J 1P3
Date of Revision:
February 14, 2008
Control No: 117121
_ _
RATIO-RISPERIDONE_ - Product Monograph _
_Page 2 of 56_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS..................................................................................................13
DRUG INTERACTIONS
..................................................................................................22
DOSAGE AND
ADMINISTRATION..............................................................................25
OVERDOSAGE
................................................................................................................28
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND
STABILITY..........................................................................................31
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................31
PART II: SCIENTIFIC INFORMATION
...............................................................................33
PHARMACEUTICAL
INFORMATION..........................................................................33
CLINICAL
TRIALS..........................................................................................................34
DETAILED
PHARMACOLOGY.......